Attached files
| file | filename |
|---|---|
| EX-99.3 - EXHIBIT 99.3 - Sucampo Pharmaceuticals, Inc. | exh_993.htm |
| EX-99.2 - EXHIBIT 99.2 - Sucampo Pharmaceuticals, Inc. | exh_992.htm |
| EX-99.1 - EXHIBIT 99.1 - Sucampo Pharmaceuticals, Inc. | exh_991.htm |
| 8-K/A - FORM 8-K/A - Sucampo Pharmaceuticals, Inc. | f8ka_051917.htm |
Exhibit 23.1
Consent of Independent Auditors
We consent to the incorporation by reference in the Registration Statements of Sucampo Pharmaceuticals, Inc.:
| (1) | Registration Statement (Form S-8 No. 333-147420) pertaining to the 2006 Employee Stock Purchase Plan, the 2006 Stock Incentive Plan, as amended and restated, and the Amended and Restated 2001 Stock Incentive Plan of Sucampo Pharmaceuticals, Inc., |
| (2) | Registration Statement (Form S-3 No. 333-201566) of Sucampo Pharmaceuticals, Inc., and |
| (3) | Registration Statement (Form S-8 No. 333-213728) pertaining to the 2016 Equity Incentive Plan of Sucampo Pharmaceuticals, Inc.; |
of our report dated March 15, 2017, with respect to the financial statements Vtesse, Inc., included in this Current Report on Form 8-K/A.
/s/ Ernst & Young LLP
Tysons, Virginia
May 22, 2017